163 related articles for article (PubMed ID: 12954116)
1. Safety of CpG oligodeoxynucleotides in veterinary species.
Ioannou XP; Griebel P; Mena A; Gomis SM; Godson DL; Mutwiri G; Hecker R; Babiuk LA; van Drunen Littel-van den Hurk S
Antisense Nucleic Acid Drug Dev; 2003; 13(3):157-67. PubMed ID: 12954116
[TBL] [Abstract][Full Text] [Related]
2. Cytosine-phosphate-guanine oligodeoxynucleotides containing GACGTT motifs enhance the immune responses elicited by keyhole limpet hemocyanin antigen in dairy cattle.
Chu CY; Lee SC; Liu SS; Lin YM; Shen PC; Yu C; Lee KH; Zhao X; Lee JW
Nucleic Acid Ther; 2011 Oct; 21(5):323-32. PubMed ID: 21916610
[TBL] [Abstract][Full Text] [Related]
3. Requirements for effective inhibition of immunostimulatory CpG motifs by neutralizing motifs.
Zhao H; Cheng SH; Yew NS
Antisense Nucleic Acid Drug Dev; 2000 Oct; 10(5):381-9. PubMed ID: 11079577
[TBL] [Abstract][Full Text] [Related]
4. Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo.
Hartmann G; Weeratna RD; Ballas ZK; Payette P; Blackwell S; Suparto I; Rasmussen WL; Waldschmidt M; Sajuthi D; Purcell RH; Davis HL; Krieg AM
J Immunol; 2000 Feb; 164(3):1617-24. PubMed ID: 10640783
[TBL] [Abstract][Full Text] [Related]
5. Structure-dependent immunostimulatory effect of CpG oligodeoxynucleotides and their delivery system.
Hanagata N
Int J Nanomedicine; 2012; 7():2181-95. PubMed ID: 22619554
[TBL] [Abstract][Full Text] [Related]
6. Co-administration of polyphosphazenes with CpG oligodeoxynucleotides strongly enhances immune responses in mice immunized with Hepatitis B virus surface antigen.
Mutwiri G; Benjamin P; Soita H; Babiuk LA
Vaccine; 2008 May; 26(22):2680-8. PubMed ID: 18430493
[TBL] [Abstract][Full Text] [Related]
7. Induction of interleukin-6 and interleukin-12 in bovine B lymphocytes, monocytes, and macrophages by a CpG oligodeoxynucleotide (ODN 2059) containing the GTCGTT motif.
Zhang Y; Shoda LK; Brayton KA; Estes DM; Palmer GH; Brown WC
J Interferon Cytokine Res; 2001 Oct; 21(10):871-81. PubMed ID: 11711000
[TBL] [Abstract][Full Text] [Related]
8. Hierarchical recognition of CpG motifs expressed by immunostimulatory oligodeoxynucleotides.
Klinman DM; Currie D
Clin Exp Immunol; 2003 Aug; 133(2):227-32. PubMed ID: 12869028
[TBL] [Abstract][Full Text] [Related]
9. Strong cytosine-guanosine-independent immunostimulation in humans and other primates by synthetic oligodeoxynucleotides with PyNTTTTGT motifs.
Elias F; Flo J; Lopez RA; Zorzopulos J; Montaner A; Rodriguez JM
J Immunol; 2003 Oct; 171(7):3697-704. PubMed ID: 14500668
[TBL] [Abstract][Full Text] [Related]
10. Three CpG oligodeoxynucleotide classes differentially enhance antigen-specific humoral and cellular immune responses in mice.
Liu Y; Luo X; Yang C; Yu S; Xu H
Vaccine; 2011 Aug; 29(34):5778-84. PubMed ID: 21664398
[TBL] [Abstract][Full Text] [Related]
11. In vivo oral administration effects of various oligodeoxynucleotides containing synthetic immunostimulatory motifs in the immune response to pseudorabies attenuated virus vaccine in newborn piglets.
Linghua Z; Xingshan T; Fengzhen Z
Vaccine; 2008 Jan; 26(2):224-33. PubMed ID: 18063448
[TBL] [Abstract][Full Text] [Related]
12. Interferon alpha and CPG oligodeoxynucleotides elicit additive immunostimulatory and antitumor effects.
Brown L; Roda J; Terrell C; Chaudhury AR; Crespin T; Carson WE; Lesinski GB
Surgery; 2006 Aug; 140(2):297-306. PubMed ID: 16904983
[TBL] [Abstract][Full Text] [Related]
13. Immune stimulation in the silkworm, Bombyx mori L., by CpG oligodeoxynucleotides.
Kim I; Kim SH; Lee YS; Yun EK; Lee HS; Kim JW; Ryu KS; Kang PD; Lee IH
Arch Insect Biochem Physiol; 2004 Jan; 55(1):43-8. PubMed ID: 14691962
[TBL] [Abstract][Full Text] [Related]
14. Monocytes are required for optimum in vitro stimulation of bovine peripheral blood mononuclear cells by non-methylated CpG motifs.
Pontarollo RA; Rankin R; Babiuk LA; Godson DL; Griebel PJ; Hecker R; Krieg AM; van Drunen Littel-van den Hurk S
Vet Immunol Immunopathol; 2002 Jan; 84(1-2):43-59. PubMed ID: 11825597
[TBL] [Abstract][Full Text] [Related]
15. Oligodeoxynucleotides containing CpG motifs can induce rejection of a neuroblastoma in mice.
Carpentier AF; Chen L; Maltonti F; Delattre JY
Cancer Res; 1999 Nov; 59(21):5429-32. PubMed ID: 10554011
[TBL] [Abstract][Full Text] [Related]
16. CpG oligodeoxynucleotides as DNA adjuvants in vertebrates and their applications in immunotherapy.
Chaung HC
Int Immunopharmacol; 2006 Oct; 6(10):1586-96. PubMed ID: 16919831
[TBL] [Abstract][Full Text] [Related]
17. Strategies for enhancing the immunostimulatory effects of CpG oligodeoxynucleotides.
Mutwiri GK; Nichani AK; Babiuk S; Babiuk LA
J Control Release; 2004 May; 97(1):1-17. PubMed ID: 15147800
[TBL] [Abstract][Full Text] [Related]
18. Nanodelivery systems for enhancing the immunostimulatory effect of CpG oligodeoxynucleotides.
Zhang H; Gao XD
Mater Sci Eng C Mater Biol Appl; 2017 Jan; 70(Pt 2):935-946. PubMed ID: 27772724
[TBL] [Abstract][Full Text] [Related]
19. Influence of orally administered CpG-ODNs on the humoral response to bovine serum albumin (BSA) in chickens.
Ameiss KA; El Attrache J; Barri A; McElroy AP; Caldwell DJ
Vet Immunol Immunopathol; 2006 Apr; 110(3-4):257-67. PubMed ID: 16387368
[TBL] [Abstract][Full Text] [Related]
20. CpG DNA as a vaccine adjuvant.
Bode C; Zhao G; Steinhagen F; Kinjo T; Klinman DM
Expert Rev Vaccines; 2011 Apr; 10(4):499-511. PubMed ID: 21506647
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
